Shield Therapeutics PLC
LSE:STX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Easun Reyrolle Ltd
NSE:EASUNREYRL
|
IN |
Shield Therapeutics PLC
PP&E Net
Shield Therapeutics PLC
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shield Therapeutics PLC
LSE:STX
|
PP&E Net
£113k
|
CAGR 3-Years
-22%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
PP&E Net
£10B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
|
|
AstraZeneca PLC
LSE:AZN
|
PP&E Net
$14.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
PP&E Net
$1.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
PP&E Net
£24.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
PP&E Net
£5.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
30%
|
|
Shield Therapeutics PLC
Glance View
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
See Also
What is Shield Therapeutics PLC's PP&E Net?
PP&E Net
113k
GBP
Based on the financial report for Dec 31, 2025, Shield Therapeutics PLC's PP&E Net amounts to 113k GBP.
What is Shield Therapeutics PLC's PP&E Net growth rate?
PP&E Net CAGR 10Y
19%
Over the last year, the PP&E Net growth was -70%. The average annual PP&E Net growth rates for Shield Therapeutics PLC have been -22% over the past three years , 29% over the past five years , and 19% over the past ten years .
